

FLUIDIGM CORP  
Form 8-K  
September 13, 2016

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8 K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported)  
September 7, 2016

FLUIDIGM CORPORATION  
(Exact name of registrant as specified in its charter)

|  |                          |                                   |
|--|--------------------------|-----------------------------------|
| Delaware                                       | 001-34180                | 77-0513190                        |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

7000 Shoreline Court, Suite 100  
South San Francisco, California 94080  
(Address of principal executive offices, including zip code)  
(650) 266-6000  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

Item 5.02 – Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 7, 2016, Marc Unger, our Executive Vice President, Research and Development and Marketing, indicated his decision to take an approximately 10-week leave of absence from Fluidigm Corporation (the “Company”) commencing October 1, 2016. The Company and Dr. Unger intend to enter into a part-time consulting engagement, commencing in December 2016 following Dr. Unger’s leave, and are currently in discussions regarding the terms of the leave and such consulting or other arrangement.

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FLUIDIGM  
CORPORATION

Date: September 13, 2016 By: /s/ Nicholas Khadder  
Nicholas Khadder  
General Counsel and  
Secretary